Combination Treatment of Rituximab and Plasmapheresis in Acute Cellular Rejection with Focal Segmental Glomerular Sclerosis after Renal Transplantation.
10.4285/jkstn.2010.24.1.30
- Author:
Ji Min JEON
1
;
Joon Suk OH
;
Sung Min KIM
;
Yoong Gi SON
;
Yong Ki PARK
;
Yong Hun SIN
;
Joong Kyung KIM
;
Yong Jin KIM
Author Information
1. Division of Nephrology, Department of Internal Medicine, Bong Seng Memorial Hospital, Busan, Korea. syhpmj@hanmail.net
- Publication Type:Case Report
- Keywords:
FSGS;
Rituximab;
Kidney transplantation
- MeSH:
Antibodies, Monoclonal, Murine-Derived;
Biopsy;
Creatinine;
Female;
Humans;
Kidney Diseases;
Kidney Transplantation;
Living Donors;
Middle Aged;
Plasmapheresis;
Proteinuria;
Recurrence;
Rejection (Psychology);
Rituximab;
Sclerosis;
Transplantation, Homologous;
Transplants
- From:The Journal of the Korean Society for Transplantation
2010;24(1):30-34
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Focal segmental glomerular sclerosis (FSGS) accounts for recurrence in 20% to 40% of the renal allografts after transplantation, and it causes graft loss in 13% to 20% of the cases. We report here on successfully treating acute cellular rejection (ACR) combined with FSGS after a kidney transplantation with a combination treatment of plasmapheresis, rituximab and steroid pulse therapy. A 53-year-old female patient whose primary kidney disease was unknown developed massive proteinuria after living donor kidney transplantation. A urine protein/creatinine ratio of 13.42 and an elevated serum creatinine level was detected on postoperative days (POD) 10 and a renal biopsy showed acute cellular rejection (Banff IIb) combined with FSGS. We started steroid pulse therapy on POD 11. She underwent 5 plasmapheresis sessions in the first 3 week after transplantation and she received one dose of rituximab (375 mg/m2) on POD 12. The proteinuria decreased below the nephrotic range at POD 20 and the serum creatinine level was normalized. Three months later, the proteinuria was at 35 mg/day with stable graft function. Rituximab and plasmapheresis is a possible option to treat FSGS combined with a relapse of proteinuria after renal transplantation.
